Skip to main content

Eli Greenspan

ML Strategies - Manager of Government Relations

[email protected]

+1.202.434.7420

Share:

Prior to joining ML Strategies, Eli was a legislative correspondent for US Senator Martin Heinrich (D-NM), where his experience included health care, education, child welfare, social security, food assistance, and poverty issues specifically as they relate to the Affordable Care Act, Medicare, and Social Security. Previously, Eli served as a legislative intern with Senator Heinrich. He also served as a legislative intern with Senator Dick Durbin (D-IL), where he worked on issues related to education, health, and commerce. Eli has also served as an intern at a political fundraising and strategy firm in Chicago.

Outside of politics, Eli was the founder of MLB Daily Dish, a blog devoted to Major League Baseball. He also was the lead sports writer for ChicagoNow’s Down on the Farm, where he covered the Cubs and White Sox minor league teams

Education

  • University of Maryland (BA)

Recognition & Awards

  • Yitzhak Rabin Memorial Fellow (2011 – 2012)

Recent Insights

News & Press

Viewpoints

Viewpoint

ML Strategies Health Care Preview: Government Shutdown Looming?

September 27, 2019 | Blog | By Eli Greenspan

Congress has just days to pass a continuing resolution to avoid a government shutdown and extend a number of key public health programs. Meanwhile, policymakers are holding hearings and considering a series of drug pricing proposals around negotiation within Medicare and other policies. We cover this and more in this week's preview, which you can find by clicking here.
Viewpoint

ML Strategies Health Care Preview: Surprise Billing Issue Heats Up

September 16, 2019 | Blog | By Eli Greenspan, Alexander Hecht

This week, Congress is working towards passage of a continuing resolution that would fund the government through the middle of November. This will give policymakers and appropriators enough time to hash out differences in funding priorities as well as work on policies addressing drug pricing, surprise billing, and funding for public health programs. The surprise billing issue is really heating up with outside stakeholder groups weighing in and Congress carefully considering its next steps. We cover this and more in this week's preview, which you can find by clicking here.
Viewpoint

Senate Finance Committee Passes Drug Pricing Bill

July 30, 2019 | Blog | By Theresa Carnegie, Ellyn Sternfield, Matt Mora, Michelle Caton, Eli Greenspan

Senators Chuck Grassley (R-IA) and Ron Wyden (D-OR), Chairman and Ranking Member (respectively) of the Senate Finance Committee, have fired the latest shot in Congress’s ongoing battle against high drug prices. Last week, the Senators introduced their much-anticipated proposal to lower drug prices: a chairman’s mark called the Prescription Drug Pricing Reduction Act (PDPRA) of 2019.

Viewpoint General

ML Strategies Health Care Preview: August Recess in Sight

July 29, 2019 | Blog | By Eli Greenspan

This week, the Senate is expected to vote on a budget deal that would also suspend the debt limit for two years. This clears a major hurdle come September when both chambers of Congress will be in session with a laundry list of policies and programs to address, including appropriations. We cover this and more in this week's preview, which you can find by clicking here. 
Viewpoint
This week, the House is set to vote on repeal of the Cadillac tax, which is a forty-percent tax on high-cost health plans established by the Affordable Care Act. While its prospects for passage in the Senate are not entirely clear, passage out of the House clears an important hurdle. In other news, we are continuing to monitor the evolving drug pricing debate which is still expected to ramp up in the coming weeks with action from the Administration and Senate.
Viewpoint General

ML Strategies Health Care Preview: ACA Oral Arguments to Begin

July 8, 2019 | Blog | By Eli Greenspan, Alexander Hecht

This week, the Affordable Care Act (ACA) is back in the news with oral arguments set to begin before the U.S. Court of Appeals for the Fifth Circuit. The court will decide whether to uphold a federal district court's ruling that struck down the ACA. This case has the potential to reshape the political landscape in 2020 if it reaches the Supreme Court. On Capitol Hill, policymakers are working hard to bring forth a drug pricing package before the August recess. They will also have to balance the Administration's efforts, which is expected to issue an executive order this month on lowering drug costs. We cover this and more in this week's preview. 
Viewpoint General
This week, the House Energy & Commerce Committee is voting on seven more drug pricing bills. The Senate is going to be unveiling its cost-containment package in the coming weeks (if not days) and should include most, if not all, of the House-passed drug pricing bills. This action will set the stage for the summer work period, which is expected to focus heavily on drug pricing and other cost-containment measures, such as surprise medical bills. At CMS, the agency published a final rule last week that touched on several noteworthy drug pricing issues. We cover this and more in this week's preview, which you can find by clicking here. 
Viewpoint General

ML Strategies Health Care Preview: Congress's Summer Plans Filling Up Fast

May 13, 2019 | Blog | By Eli Greenspan, Alexander Hecht

Congress is circling an issue that is not black and white in terms of the stakeholders it could impact and how interests will align. The leaders of the Senate Health, Education, Labor, and Pensions Committee and the Senate Finance Committee are poised to release a cost-containment package in the coming weeks which will touch on surprise billing issues, drug pricing, and other access and transparency issues. While there is intense bipartisan interest in addressing some of these issues, it is unclear how exactly this package will reach the President's desk given the current political climate.
Viewpoint General

ML Strategies Health Care Preview: House Poised to Pass First Drug Pricing Bills

May 8, 2019 | Blog | By Eli Greenspan, Alexander Hecht

This week, the House is poised to take action on drug pricing by passing two pieces of legislation. As the House moves bills through final passage, focus will shift to the Senate which will in the coming weeks unveil a legislative package around lowering costs for consumers. The scope of this package is still unclear, but it should include a number of proposals that could pass on a bipartisan basis. We cover this and more in this week's preview, which you can find by clicking here. 
Viewpoint General

MLS Weekly Preview: Medicare For All Gets a Hearing

April 29, 2019 | Blog | By Eli Greenspan, Alexander Hecht

Following the two week recess, Congress is back in session and will have several high profile hearings this week. For starters, the Energy & Commerce Health subcommittee will continue reviewing prescription drug costs, this time focusing in on Medicare. In the Rules Committee, which does not typically host high profile hearings, they will hold the first committee hearing on H.R. 1384, one of the "Medicare for All" proposals.


The House is poised to pass several noteworthy drug pricing bills this work period, as well as legislation to strengthen the Affordable Care Act. Once the House votes on these bills, the question will then become what is the Senate able to pass and what is their appetite for taking it on this summer. We cover this and more in this week's preview.

News & Press

ML Strategies Executive VP & Director of Operations Alex Hecht and Manager of Government Relations Eli Greenspan authored this HFMA Advisor article discussing the impact that states transitioning their Medicaid populations into managed care has had on individuals with traumatic brain injuries.
Alex Hecht, ML Strategies Executive Vice President and Director of Operations; Eli Greenspan, ML Strategies Manager of Government of Relations; and Rodney Whitlock, ML Strategies Vice President, authored a Physician Solutions Magazine article discussing growing interest in telemedicine.